Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.65 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.65 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
| ▸ | MST1R | Q04912 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15090755 | 0.90 | EGFR (0.82) | EGFRERBB2ERBB4RET | |
| SCHEMBL15106846 | 0.85 | EGFR (0.61) | EGFRERBB2 | |
| SCHEMBL15090694 | 0.84 | EGFR (0.59) | EGFR | |
| SCHEMBL15090537 | 0.82 | EGFR (1.00) | EGFRERBB2ERBB4RET | |
| SCHEMBL15781150 | 0.79 | EGFR (0.65) | EGFRERBB2ERBB4RETMST1R | |
| SCHEMBL25859436 | 0.79 | EGFR (0.90) | EGFRERBB2ERBB4 | |
| SCHEMBL14149367 | 0.78 | EGFR (0.64) | EGFRERBB2ERBB4RETMST1R | |
| SCHEMBL15090717 | 0.78 | EGFR (0.73) | EGFRERBB2ERBB4RET | |
| SCHEMBL18633102 | 0.77 | EGFR (0.51) | EGFRERBB2 | |
| SCHEMBL15876908 | 0.77 | EGFR (0.69) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10507209-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | XUANZHU PHARMA CO, LTD. (CN) | 2019-12-17 | — | — | US | disclosed |
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO, LTD. (CN) | 2017-11-23 | — | — | US | disclosed |
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO, LTD. (CN) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | NQO2, CHRM1, CHRM2 | EGFR 983/4885ERBB2 1417/4885ERBB4 1431/4885 |
| US-10507209-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | NQO2, CHRM1, CHRM2 | EGFR 983/4885ERBB2 1417/4885ERBB4 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.